RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Seres Therapeutics - Stock

Seres Therapeutics P/E 2024

Seres Therapeutics P/E

-0.87

Seres Therapeutics Dividend yield

Ticker

MCRB

ISIN

US81750R1023

WKN

A14VXX

As of Jun 9, 2024, Seres Therapeutics's P/E ratio was -0.87, a -84.57% change from the -5.64 P/E ratio recorded in the previous year.

The Seres Therapeutics P/E history

Seres Therapeutics Aktienanalyse

What does Seres Therapeutics do?

Seres Therapeutics Inc is a company specializing in the development of microbiome therapeutics. The company was founded in 2010 by a group of scientists from Harvard University who recognized the potential of the microbiome and were excited by the fact that it has a multitude of impacts on human health. Seres Therapeutics' headquarters are located in Cambridge, Massachusetts, USA. The business model of Seres Therapeutics is based on the research, development, and commercialization of therapeutics based on the microbiome. The microbiome is the collection of all microorganisms, including bacteria, viruses, and fungi, that live in the human body. Seres Therapeutics firmly believes that the microbiome plays a crucial role in maintaining health and aims to develop innovative therapies that can improve the immune system and strengthen the body's defenses based on this. Seres Therapeutics' products are designed for the treatment of gastrointestinal tract diseases, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. The company's products harness the potential of the microbiome to improve gut health, particularly by restoring the natural balance of gut flora. In 2016, Seres Therapeutics launched its first approved drug on the market - SER-109, a treatment for recurrent Clostridium difficile infections (CDI). CDI is an infectious disease caused by the bacterium Clostridium difficile and is commonly associated with antibiotic therapies. SER-109 has proven effective in reducing the frequency of CDI infections, making it the first approved microbiome-based therapeutic. Seres Therapeutics is also working on the development of other products. The company has conducted several Phase 2 clinical trials demonstrating the efficacy of its preparations for the treatment of inflammatory bowel disease. Other products in Seres Therapeutics' pipeline are currently being tested for their effectiveness in combating cancer and autoimmune diseases, where the microbiome also plays an important role. Seres Therapeutics is also working to expand its business into other markets. The company has entered into partnerships with leading pharmaceutical companies such as Nestlé and AstraZeneca to explore the potential of microbiome therapy in various indications. Another important initiative of Seres Therapeutics is the exploration of the use of artificial intelligence to identify new microbiome-based therapeutics and improve drug development. Overall, Seres Therapeutics Inc has written a fascinating story by recognizing the potential of the microbiome in combating diseases. The company is on track to become a leading provider of microbiome-based therapeutics and continues its efforts to provide innovative solutions to future medical challenges. Seres Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Seres Therapeutics's P/E Ratio

The Price to Earnings (P/E) Ratio of Seres Therapeutics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Seres Therapeutics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Seres Therapeutics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Seres Therapeutics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Seres Therapeutics Stock

What is the price-to-earnings ratio of Seres Therapeutics?

The price-earnings ratio of Seres Therapeutics is currently -0.87.

How has the price-earnings ratio of Seres Therapeutics changed compared to last year?

The price-to-earnings ratio of Seres Therapeutics has increased by -84.57% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Seres Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Seres Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Seres Therapeutics affect the company?

An increase in the price-earnings ratio of Seres Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Seres Therapeutics affect the company?

A decrease in the price-earnings ratio of Seres Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Seres Therapeutics?

Some factors that influence the price-earnings ratio of Seres Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Seres Therapeutics pay?

Over the past 12 months, Seres Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Seres Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Seres Therapeutics?

The current dividend yield of Seres Therapeutics is .

When does Seres Therapeutics pay dividends?

Seres Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Seres Therapeutics?

Seres Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Seres Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Seres Therapeutics located?

Seres Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Seres Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Seres Therapeutics from 6/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/9/2024.

When did Seres Therapeutics pay the last dividend?

The last dividend was paid out on 6/9/2024.

What was the dividend of Seres Therapeutics in the year 2023?

In the year 2023, Seres Therapeutics distributed 0 USD as dividends.

In which currency does Seres Therapeutics pay out the dividend?

The dividends of Seres Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Seres Therapeutics

Our stock analysis for Seres Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Seres Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.